JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

MacroGenics Inc

Geschlossen

BrancheGesundheitswesen

1.84 0.55

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.81

Max

1.87

Schlüsselkennzahlen

By Trading Economics

Einkommen

4.8M

-36M

Verkäufe

9M

22M

Gewinnspanne

-162.992

Angestellte

341

EBITDA

5.7M

-33M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+104.92% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

4. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

15M

108M

Vorheriger Eröffnungskurs

1.29

Vorheriger Schlusskurs

1.84

Nachrichtenstimmung

By Acuity

50%

50%

145 / 371 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Neutral Evidence

MacroGenics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

24. Okt. 2025, 18:41 UTC

Ergebnisse

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24. Okt. 2025, 18:31 UTC

Ergebnisse

Correction to Procter & Gamble to Focus on Innovation

24. Okt. 2025, 16:25 UTC

Wichtige Markttreiber

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24. Okt. 2025, 21:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

24. Okt. 2025, 21:24 UTC

Market Talk

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24. Okt. 2025, 21:07 UTC

Ergebnisse

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24. Okt. 2025, 20:58 UTC

Ergebnisse

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24. Okt. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 20:40 UTC

Ergebnisse

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24. Okt. 2025, 20:24 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:23 UTC

Ergebnisse

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24. Okt. 2025, 20:13 UTC

Ergebnisse

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 20:07 UTC

Market Talk

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24. Okt. 2025, 19:40 UTC

Market Talk

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24. Okt. 2025, 19:35 UTC

Market Talk

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24. Okt. 2025, 19:33 UTC

Ergebnisse

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24. Okt. 2025, 19:29 UTC

Market Talk

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24. Okt. 2025, 18:52 UTC

Ergebnisse

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:41 UTC

Ergebnisse

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24. Okt. 2025, 18:03 UTC

Ergebnisse

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24. Okt. 2025, 18:02 UTC

Ergebnisse

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24. Okt. 2025, 18:00 UTC

Market Talk

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24. Okt. 2025, 16:57 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24. Okt. 2025, 16:54 UTC

Market Talk

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24. Okt. 2025, 16:44 UTC

Market Talk
Ergebnisse

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24. Okt. 2025, 16:39 UTC

Market Talk
Ergebnisse

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24. Okt. 2025, 16:33 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:23 UTC

Ergebnisse

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24. Okt. 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

24. Okt. 2025, 16:07 UTC

Ergebnisse

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Peer-Vergleich

Kursveränderung

MacroGenics Inc Prognose

Kursziel

By TipRanks

104.92% Vorteil

12-Monats-Prognose

Durchschnitt 3.75 USD  104.92%

Hoch 5 USD

Tief 3 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für MacroGenics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

6 ratings

3

Buy

3

Halten

0

Sell

Technischer Score

By Trading Central

1.47 / 1.64Unterstützung & Widerstand

Kurzfristig

Neutral Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

145 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
help-icon Live chat